7748 Federal Register / Vol. 73, No. 28 / Monday, February 11, 2008 / Notices 

is no registration fee for the public 

workshop. Early registration is 

recommended because seating is limited 

to 175 attendees. Registration on the day 

of the public workshop will be provided 

on a space available basis beginning at 

7:30 a.m. 

If you need special accommodations 

due to a disability, please contact 

Rhonda Dawson at least 7 days in 

advance of the workshop. 

SUPPLEMENTARY INFORMATION: FDA; the 

National Heart, Lung, and Blood 

Institute, National Institutes of Health; 

and the Department of Health and 

Human Services’ Office of the Secretary 

and Office of Public Health and Science 

are co-sponsoring this public workshop. 

The primary goal of the workshop is to 

discuss what is known about the safety 

of HBOCs, and possible paths forward 

for development of these products. 

Topics to be discussed on April 29, 

2008, will include: (1) Introduction to 

the issues and unmet needs surrounding 

HBOC development, (2) overview of the 

physiology and chemistry of 

hemoglobin in HBOCs, (3) nitric oxide 

physiology and pathophysiology related 

to HBOCs, (4) review of nonclinical 

studies of HBOCs, (5) risk-benefit 

considerations in clinical trials of 

HBOCs, (6) proposed clinical 

indications for HBOCs, and (7) 

industry’s experience with HBOC 

clinical trials. Panel deliberations on the 

safety and efficacy of HBOCs in various 

clinical settings and potential 

mechanisms of effects on organs will be 

the main topics of discussion on April 

30, 2008. We also will discuss future 

development pathways with a focus on 

the use and development of animal 

models, biochemical redesign 

approaches, and alternative clinical 

designs where benefit exceeds risk. 

Please note that on January 15, 2008, 

the FDA Web site transitioned to the 

Federal Dockets Management System 

(FDMS). FDMS is a Government-wide, 

electronic docket management system. 

Electronic submissions will be accepted 

by FDA through FDMS only. 

Transcripts: Transcripts of the public 

workshop may be requested in writing 

from the Freedom of Information Office 

(HFI–35), Food and Drug 

Administration, 5600 Fishers Lane, rm. 

6–30, Rockville, MD 20857, 

approximately 15 working days after the 

public workshop at a cost of 10 cents 

per page. A transcript of the public 

workshop will be available on the 

Internet at http://www.fda.gov/cber/ 

minutes/workshop-min.htm. 

Dated: February 4, 2008. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. E8–2397 Filed 2–8–08; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Committee on 

Interdisciplinary, Community-Based 

Linkages; Notice of Request for 

Nominations 

AGENCY: Health Resources and Services 

Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Health Resources and 

Services Administration (HRSA) is 

requesting nominations to fill five (5) 

upcoming vacancies on the Advisory 

Committee on Interdisciplinary, 

Community-Based Linkages (ACICBL). 

Authority: 42 U.S.C. 294f, section 756 

of the PHS Act, as amended. The 

Advisory Committee is governed by 

provisions of Public Law (Pub. L.) 92–

463, as amended (5 U.S.C. Appendix 2) 

which sets forth standards for the 

formation and use of advisory 

committees. 

DATES: The Agency must receive 

nominations on or before March 12, 

2008. 

ADDRESSES: All nominations are to be 

submitted by mail to Louis D. 

Coccodrilli, Designated Federal Official, 

ACICBL, Bureau of Health Professions 

(BHPr), HRSA, Parklawn Building, 

Room 9–05, 5600 Fishers Lane; 

Rockville, MD 20857. 

FOR FURTHER INFORMATION CONTACT: 

Adriana Guerra, Public Health Fellow, 

Division of Medicine and Dentistry, by 

e-mail aguerra@hrsa.gov or telephone, 

(301) 443–6194. 

SUPPLEMENTARY INFORMATION: Under the 

authorities that established the ACICBL, 

the Federal Advisory Committee Act of 

October 6, 1972 (Pub. L. 92–463), and 

section 2119 of the Act, 42 U.S.C. 00aa–

19, as added by Pub. L. 99–660 and 

amended, HRSA is requesting 

nominations for five (5) voting 

members. 

The ACICBL provides advice and 

recommendations to the Secretary and 

to the Congress concerning policy, 

program development and other matters 

of significance related to 

interdisciplinary, community-based 

training grant programs authorized 

under sections 751–756, Title VII, Part 

D of the Public Health Service Act. The 

ACICBL prepares an annual report 

describing the activities conducted 

during the fiscal year, identifying 

findings and developing 

recommendations to enhance Title VII 

Interdisciplinary, Community-Based 

Training Grant Programs. The Annual 

Report is submitted to the Secretary of 

the U.S. Department of Health and 

Human Services, and ranking members 

of the Committee on Health, Education, 

Labor and Pensions of the Senate, and 

the Committee on Energy and 

Commerce of the House of 

Representatives. 

The Department of Health and Human 

Services is requesting a total of five (5) 

nominations for voting members of the 

ACICBL from schools that have 

administered or are currently 

administering awards from the 

following programs: Allied Health—one 

(1) nominee, Geriatric Education and 

Training Programs—one (1) nominee, 

and Health Education and Training 

Centers (HETCs)—one (1) nominee. 

Nominations are also requested for two 

(2) students, residents, and/or fellow 

representatives. 

The legislation governing this 

Committee requires a fair balance of 

health professionals who represent the 

general population with regard to a 

broad geographic distribution and an 

evenness of urban and rural areas, along 

with professionals who are women and 

minorities. As such, the pool of 

appropriately qualified nominations 

should reflect these requirements to the 

degree possible. 

Interested individuals may nominate 

multiple qualified professionals for 

membership to the ACICBL to allow the 

Secretary a diverse listing of highly 

qualified potential candidates. 

Nominees willing to serve as members 

of the ACICBL should not have an 

appearance of a conflict of interest that 

would preclude their participation. 

Potential candidates will be asked to 

provide detailed information concerning 

consultancies, research grants, or 

contracts to permit an evaluation of 

possible sources of conflicts of interest. 

In addition, a curriculum vitae and a 

statement of interest will be required of 

the nominee to support experience 

working with Title VII Interdisciplinary, 

Community-Based Training Grant 

Programs, expertise in the field, and 

personal desire in participating on a 

National Advisory Committee. Qualified 

candidates will be invited to serve a two 

or three-year term. All nominations 

must be received no later than March 

12, 2008. 


rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 73, No. 28 / Monday, February 11, 2008 / Notices 7749 

Dated: February 5, 2008. 

Alexandra Huttinger, 

Acting Director, Division of Policy Review 

and Coordination. 

[FR Doc. E8–2396 Filed 2–8–08; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following meeting 

of the President’s Cancer Panel. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in section 

552b(c)(9)(B), Title 5 U.S.C., as 

amended, because the premature 

disclosure of information and the 

discussions would be likely to 

significantly frustrate implementation of 

recommendations. 

Name of Committee: President’s Cancer 

Panel. 

Date: March 5, 2008. 

Time: 1 p.m. to 3 p.m. 

Agenda: The panel will discuss the report 

format and recommendations for the 2007–

2008 meeting series. 

Place: National Cancer Institute, Office of 

the Director, National Institutes of Health, 

6116 Executive Blvd., Suite 212, Bethesda, 

MD 20892. (Teleconference.) 

Contact Person: Abby Sandler, PhD, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Blvd., Suite 212, Bethesda, MD 

20892, 301–451–9399. 

Any interested person may file written 

comments with the committee by forwarding 

the comments to the Contact Person listed on 

this notice. The comments should include 

the name, address, telephone number and, 

when applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/pcp/pcp.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 1, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–581 Filed 2–8–08; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Biorepository and Limited Access Data Set 

Information Coordinating Center. 

Date: March 3, 2008. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Hilton Washington Dulles Airport 

Hotel, 13869 Park Center Road, Herndon, VA 

20171. 

Contact Person: David A. Wilson, PhD, 

Scientific Review Administrator, Review 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7204, Bethesda, MD 20892–7924, (301) 435–

0299, wilsonda2@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Mentored Clinical Scientist Research Career 

Development Awards. 

Date: March 13–14, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crystal City Marriott, 1999 Jefferson 

Davis Highway, Arlington, VA 22202. 

Contact Person: Rina Das, PhD, Scientific 

Review Administrator, Review Branch/ 

DERA, National Heart, Lung, and Blood 

Institute, 6701 Rockledge Drive, Room 7200 

Bethesda, MD 20892–7924, (301) 435–0297, 

dasr2@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Ancillary Studies in Clinical Trials. 

Date: March 25, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Yingying Li-Smerin, MD, 

PhD, Scientific Review Administrator, 

Review Branch/DERA, National Heart, Lung, 

and Blood Institute, 6701 Rockledge Drive, 

Room 7184, Bethesda, MD 20892–7924, (301) 

435–0277, lismerin@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Exploratory/Developmental Grants Phase II 

(R 33’s). 

Date: March 27–28, 2008. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Georgetown, 2101 

Wisconsin Avenue, NW., Washington, DC 

20007. 

Contact Person: Keith A. Mintzer, PhD, 

Scientific Review Administrator, Review 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7186, Bethesda, MD 20892–7924, (301) 435–

0280, mintzerk@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: February 1, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–586 Filed 2–8–08; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 


rwilkins on PROD1PC63 with NOTICES